Raynaud's phenomenon in an adolescent probably induced by lisdexamfetamine

Downloads

Published

2023-02-28

How to Cite

Díaz de la Peña, A., Martín-Gil, E., & Caminal-Montero, L. (2023). Raynaud’s phenomenon in an adolescent probably induced by lisdexamfetamine. Revista De Psiquiatría Infanto-Juvenil, 40(1), 31–34. https://doi.org/10.31766/revpsij.v40n1a4

Issue

Vol. 40 No. 1 (2023): Enero-Marzo

Section

Case reports

License

Copyright (c) 2023 Revista de Psiquiatría Infanto-Juvenil

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Crossref
Scopus
Google Scholar
Europe PMC

Authors

  • Alicia Díaz de la Peña CSM infanto-juvenil. Área de Gestión Clínica de Salud Mental, Hospital Universitario Central de Asturias, Oviedo https://orcid.org/0000-0003-4357-8366
  • Elena Martín-Gil UGC Medicina Interna. Hospital Universitario Central de Asturias, Oviedo. Instituto de Investigación Sanitaria del Principado de Asturias (ISPA) https://orcid.org/0000-0002-9055-5856
  • Luis Caminal-Montero UGC Medicina Interna. Hospital Universitario Central de Asturias, Oviedo. Instituto de Investigación Sanitaria del Principado de Asturias (ISPA) https://orcid.org/0000-0002-4044-8235

DOI:

https://doi.org/10.31766/revpsij.v40n1a4

Keywords:

Attention deficit hyperactivity disorder, Raynaud’s phenomenon, Lisdexamfetamine, Adolescent

Abstract

We report the case of a 13-year-old male who presented with a history of attention-deficit hyperactivity disorder and Raynaud phenomena after treatment with lisdexamfetamine. Clinicians should be aware of the potential vascular side effects of stimulant medications, and how to handle them.

Downloads

Download data is not yet available.

References

Cortese S. Pharmacologic Treatment of Attention Deficit–Hyperactivity Disorder. N Engl J Med. 2020 Sep 10;383(11): 1050-6. https://doi.org/10.1056/NEJMra1917069 DOI: https://doi.org/10.1056/NEJMra1917069

Alda Díez JA. Los retos del TDAH. Rev Psiquiatr Infanto-Juv. 2022;39(1): 1-2. https://doi.org/10.31766/revpsij.v39n1a1 DOI: https://doi.org/10.31766/revpsij.v39n1a1

Ordovás M, Rodríguez Jiménez E, Burgos R, Roldán R. Vasculopatía periférica asociada al tratamiento con metilfenidato en niños con Trastorno por déficit de atención e hiperactividad. Rev Psiquiatr Infanto-Juv. 2014;31(4): 36-42. https://www.aepnya.eu/index.php/revistaaepnya/article/view/134

Khouri C, Blaise S, Carpentier P, Villier C, Cracowski J-L, Roustit M. Drug-induced Raynaud’s phenomenon: beyond B-adrenoceptor blockers: Drug-induced Raynaud’s phenomenon. Br J Clin Pharmacol. 2016;82: 6-16. https://doi.org/10.1111/bcp.12912 DOI: https://doi.org/10.1111/bcp.12912

Laboe C, Batchelder E, Vasireddy D. Persistent Raynaud’s Phenomenon Following Methylphenidate Hydrochloride Use During the COVID-19 Pandemic. Cureus. 2021;13. https://doi.org/10.7759/cureus.17647 DOI: https://doi.org/10.7759/cureus.17647

Frampton JE. Lisdexamfetamine: A Review in ADHD in Adults. CNS Drugs. 2016;30:343-54. https://doi.org/10.1007/s40263-016-0327-6 DOI: https://doi.org/10.1007/s40263-016-0327-6

PROSPECTO ELVANSE 30 MG CAPSULAS DURAS. Disponible en https://cima.aemps.es/cima/dochtml/p/77642/Prospecto_77642.html. Acceso 15 de septiembre de 2022.

Goldman W, Seltzer R, Reuman P. Association between treatment with central nervous system stimulants and Raynaud’s syndrome in children: A retrospective case–control study of rheumatology patients. Arthritis & Rheumatism. 2008;58: 563-6. https://doi.org/10.1002/art.23301 DOI: https://doi.org/10.1002/art.23301

Gnanavel S. Lisdexamfetamine and Secondary Raynaud’s Phenomenon. Prim Care Companion CNS Disord. 2018;20: 27425. https://doi.org/10.4088/PCC. 17l02240 DOI: https://doi.org/10.4088/PCC.17l02240

Umair HM, Sandler RD, Alunno A, Matucci-Cerinic M, Hughes M. Association between central nervous system stimulants used to treat attention deficit hyperactivity disorder (ADHD) and Raynaud’s phenomenon: A scoping review. Semin Arthritis Rheum. 2021;51: 200-4. https://doi.org/10.1016/j.semarthrit.2021. 09.002 DOI: https://doi.org/10.1016/j.semarthrit.2021.09.002

Reacciones Adversas a Medicamentos. Lisdexanfetamina (Elvanse). Boletín Informativo del Centro de Farmacogivilancia de la Comunidad de Madrid.2018. https://seguridadmedicamento.sanidadmadrid.org/RAM/vol-25/2-2-Vol25n1abr2018.pdf